Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures

NCT00524030 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

161

Enrollment

INDUSTRY

Sponsor class

Stopped See termination reason in detailed description.

Conditions

Epilepsies, Partial

Interventions

DRUG: pregabalin 600 mg/day
DRUG: pregabalin 150 mg/day

Sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.